- Home
- ELTX vs SRBK Comparison
ELTX vs SRBK Comparison
Compare ELTX & SRBK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELTX
- SRBK
- Stock Information
- Founded
- ELTX 2011
- SRBK 1887
- Country
- ELTX United States
- SRBK United States
- Employees
- ELTX N/A
- SRBK N/A
- Industry
- ELTX Biotechnology: Pharmaceutical Preparations
- SRBK
- Sector
- ELTX Health Care
- SRBK
- Exchange
- ELTX Nasdaq
- SRBK Nasdaq
- Market Cap
- ELTX 121.7M
- SRBK 117.4M
- IPO Year
- ELTX N/A
- SRBK N/A
- Fundamental
- Price
- ELTX $7.91
- SRBK $13.51
- Analyst Decision
- ELTX Strong Buy
- SRBK
- Analyst Count
- ELTX 2
- SRBK 0
- Target Price
- ELTX $9.50
- SRBK N/A
- AVG Volume (30 Days)
- ELTX 54.3K
- SRBK 122.3K
- Earning Date
- ELTX 08-12-2025
- SRBK 07-25-2025
- Dividend Yield
- ELTX N/A
- SRBK 0.74%
- EPS Growth
- ELTX N/A
- SRBK N/A
- EPS
- ELTX N/A
- SRBK N/A
- Revenue
- ELTX N/A
- SRBK $27,988,000.00
- Revenue This Year
- ELTX N/A
- SRBK N/A
- Revenue Next Year
- ELTX N/A
- SRBK N/A
- P/E Ratio
- ELTX N/A
- SRBK N/A
- Revenue Growth
- ELTX N/A
- SRBK 23.80
- 52 Week Low
- ELTX $3.34
- SRBK $9.12
- 52 Week High
- ELTX $9.99
- SRBK $13.65
- Technical
- Relative Strength Index (RSI)
- ELTX 60.62
- SRBK 62.32
- Support Level
- ELTX $7.57
- SRBK $13.40
- Resistance Level
- ELTX $8.09
- SRBK $13.29
- Average True Range (ATR)
- ELTX 0.31
- SRBK 0.17
- MACD
- ELTX -0.09
- SRBK 0.04
- Stochastic Oscillator
- ELTX 65.15
- SRBK 95.89
About ELTX Elicio Therapeutics Inc.
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants, and vaccines for an array of aggressive cancers. It has developed its cancer vaccine product candidates to target biologically validated tumor mutation drivers using known neoantigens.
About SRBK SR Bancorp Inc. Common stock
SR Bancorp Inc principal business is to acquire deposits from individuals and businesses in the communities surrounding offices and to use these deposits to fund loans.